Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 8,135 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 8,135 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $30.01, for a total transaction of $244,131.35. Following the completion of the transaction, the chief executive officer owned 419,173 shares of the company’s stock, valued at $12,579,381.73. This trade represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $30.03 on Wednesday. The company’s 50 day simple moving average is $34.46 and its two-hundred day simple moving average is $27.22. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. Travere Therapeutics, Inc. has a 1 year low of $12.91 and a 1 year high of $42.13. The stock has a market capitalization of $2.69 billion, a PE ratio of -28.33, a P/E/G ratio of 0.98 and a beta of 0.85.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The firm had revenue of $164.86 million during the quarter, compared to analyst estimates of $106.09 million. During the same period in the previous year, the business earned ($0.70) EPS. The business’s revenue for the quarter was up 162.1% on a year-over-year basis. Analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TVTX has been the subject of a number of research analyst reports. Zacks Research lowered Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Piper Sandler lifted their target price on shares of Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Citigroup raised their price objective on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective on shares of Travere Therapeutics in a report on Friday, November 28th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.86.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in shares of Travere Therapeutics in the second quarter worth approximately $33,000. First Horizon Corp purchased a new stake in Travere Therapeutics during the 3rd quarter valued at $36,000. Headlands Technologies LLC bought a new stake in Travere Therapeutics in the 2nd quarter worth $73,000. Atria Investments Inc purchased a new position in shares of Travere Therapeutics in the second quarter valued at about $154,000. Finally, Gallagher Fiduciary Advisors LLC bought a new position in shares of Travere Therapeutics during the second quarter valued at about $155,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.